As I discussed in recent blogs, there is a surge of new immune-oncology technologies that help the body’s immune system identify and attack cancer tumours. The precision of such technologies will be crucial to refining and personalising cancer treatment for the 21st century.
Our knowledge of cancer has greatly improved in the last two decades. This has revealed the huge variability that can be found between not only different types of cancer, but also between patients with the same type of cancer. It is now evident that there is no single ‘cure’ for cancer and it has become…
NHS England has announced that it will follow NHS Scotland and Wales by implementing an HPV school vaccination programme for boys aged 12 in school year 8 from September. Girls of that age have been on the school vaccination schedule since 2008. As over 90% of Cervical cancers are caused by HPV, in approximately 40…
Further to my recent blog on Understanding Immunotherapy and the therapeutic use of oncolytic viruses as a immunotherapeutic treatment, the possibility of the use of the common cold virus, (Coxsackievirus A21), as a novel treatment agent in bladder cancer has hit the news. The results of a small study by University of Surrey researchers were…